Abstract There is accumulating evidence for the role of brain-derived neurotrophic factor (BDNF) in the pathophysiology of depression. However, the role of BDNF in the pathophysiology of post-traumatic stress disorder (PTSD) remains controversial, and no study has assessed BDNF concentrations among pregnant women with PTSD. We examined early-pregnancy BDNF concentrations among women with PTSD with and without depression. A total of 2928 women attending prenatal care clinics in Lima, Peru, were recruited. Antepartum PTSD and depression were evaluated using PTSD Checklist-Civilian Version (PCL-C) and Patient Health Questionnaire-9 (PHQ-9) scales, respectively. BDNF concentrations were measured in a subset of the cohort (N = 944) using a competitive enzyme-linked immunosorbent assay (ELISA). Logistic regression procedures were used to estimate odds ratios (OR) and 95 % confidence intervals (95 % CI). Antepartum PTSD (37.4 %) and depression (27.6 %) were prevalent in this cohort of low-income pregnant Peruvian women. Approximately 19.9 % of participants had comorbid PTSD-depression. Median serum BDNF concentrations were lower among women with comorbid PTSDdepression as compared with women without either condition (median [interquartile range], 20.44 [16.97-24.30] vs. 21.35 [17.33-26.01] ng/ml; P = 0.06). Compared to the referent group (those without PTSD and depression), women with comorbid PTSD-depression were 1.52-fold more likely to have low (<25.38 ng/ml) BDNF concentrations (OR = 1.52; 95 % CI 1.00-2.31). We observed no evidence of reduced BDNF concentrations among women with isolated PTSD. BDNF concentrations in early pregnancy were only minimally and non-significantly reduced among women with antepartum PTSD. Reductions in BDNF concentrations were more pronounced among women with comorbid PTSD-depression.
Introduction
Post-traumatic stress disorder (PTSD) is a complex syndrome resulting from exposure to life-threatening events such as war, childhood adversity, physical and/or sexual abuse, car accidents, and earthquakes or other natural disasters (American Psychiatric Association 2013). The lifetime prevalence of PTSD in the general population is estimated to be between 6 and 8 % (Kessler et al. 1995 (Kessler et al. , 2005 Pietrzak et al. 2011) . Women, as compared with men, have a greater risk of PTSD (Kessler et al. 1995; Breslau et al. 1997; Tolin and Foa 2006; Pietrzak et al. 2011) , and the risks are particularly elevated during reproductive years. Of note, investigators have reported that PTSD symptoms are likely to peak closer to the time of parturition (Onoye et al. 2013) . Overall, the prevalence of PTSD during pregnancy is estimated to be 2-26 % (Ross and Mclean 2006) . Maternal antepartum PTSD has been associated with inadequate prenatal care (Kim et al. 2006) , smoking during pregnancy (Lopez et al. 2011 ) and adverse infant outcomes such as preterm birth (Lipkind et al. 2010; Seng et al. 2011; Yonkers et al. 2014; Shaw et al. 2014) , and low birth weight (Lipkind et al. 2010; Seng et al. 2011 ).
Brain-derived neurotrophic factor (BDNF), a neurotrophin that is involved in neuronal cell growth, survival, and synaptic plasticity (Binder and Scharfman 2004) , is important for brain development, plasticity, and maintenance of neurons in adult life (Lewin and Barde 1996) and plays a critical role in the formation of long-term memory and other cognitive processes (Ernfors et al. 1990) . A growing body of evidence indicates that patients with psychiatric disorders have altered peripheral BDNF concentrations, especially those with schizophrenia (Asevedo et al. 2013) , depression (Castren and Rantamaki 2010; Bocchio-Chiavetto et al. 2010) , and PTSD (Dell'Osso et al. 2009 ).
To date, however, no study has examined BDNF concentrations in pregnant women with PTSD. Our group has previously evaluated a sample of pregnant women and showed that BDNF concentrations were reduced in women with antepartum depression (Fung et al. 2015) . However, it is currently unknown whether BDNF concentrations are altered in women with PTSD symptomology with and without comorbid depression. Therefore, the objectives of this study were to (1) estimate the prevalence of antepartum PTSD among Peru women in early pregnancy and (2) examine the extent to which, if at all, serum BDNF concentrations are associated with antepartum PTSD with and without comorbid depression.
Methods The PrOMIS cohort study
The sample for the present study was drawn from participants of the ongoing Pregnancy Outcomes, Maternal and Infant Study (PrOMIS) Cohort, designed to examine maternal social and behavioral risk factors of preterm birth and other adverse pregnancy outcomes. The study population consists of women attending prenatal care clinics at the Instituto Nacional Materno Perinatal (INMP) in Lima, Peru. The INMP is the primary reference establishment for maternal and perinatal care operated by the Ministry of Health of the Peruvian government. Recruitment began in February 2012. Women eligible for inclusion were those who initiated prenatal care prior to 16 weeks gestation. Women were ineligible if they were younger than 18 years of age, did not speak and read Spanish, or had completed more than 16 weeks gestation.
Enrolled participants were invited to participate in an interview where trained research personnel used a structured questionnaire to elicit information regarding maternal sociodemographic and lifestyle characteristics, medical and reproductive histories, and early life experiences of abuse and symptoms of mood and anxiety disorders. All participants provided written informed consent. The institutional review boards of the INMP, Lima, Peru, and the Harvard T.H. Chan School of Public Health Office of Human Research Administration, Boston, MA, USA, approved all procedures used in this study.
Analytical population
The study population for this report is derived from information collected from those participants who were enrolled in the PrOMIS Study between February 2012 and March 2014. During this period, 3541 eligible women were approached, and 3045 (86 %) agreed to participate. Of those enrolled, 117 participants did not complete the interview. Consequently, our estimation of antepartum PTSD prevalence for this cohort is based on a population of 2928 pregnant women.
Maternal serum samples for a subgroup of the study cohort (i.e., the first 982 participants in study) were selected and BDNF concentrations were measured. After excluding women with missing information concerning PTSD symptoms, a total of 944 women had both PTSD information and BDNF concentrations available for study. Women excluded from these analyses did not differ in regard to socio-demographic and lifestyle characteristics as compared with those included.
Post-traumatic stress disorder
The Post-traumatic Stress Disorder Checklist-Civilian Version (PCL-C) was used to assess PTSD symptomatology. The PCL-C assesses PTSD using 17 items designed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria (Weathers et al. 1991) . For each item, the participants are asked to indicate how much they have been bothered by each symptom over the past month on a 5-point Likert scale categorized as 1 (not at all), 2 (a little bit), 3 (moderately), 4 (quite a bit), and 5 (extremely) in regard to their most significant life event stressor. The PCL-C total score (i.e., sum of scores for the 17 items) ranges from 17 to 85. The PCL-C has been shown to have excellent internal consistency, inter-rater reliability, test-retest reliability, and convergent validity among both clinical and non-clinical populations (Wilkins et al. 2011; Conybeare et al. 2012; Mueser et al. 2001) . The Spanish-language version of the PCL-C has been shown to have psychometric properties roughly similar to those reported for the English-language version (Marshall 2004) . Findings from a study in our PrOMIS cohort indicate that a score of 26 will lead to good diagnostic efficiency with a sensitivity of 0.86 and a specificity of 0.63 (personal communication). Thus, in the present analysis, we used a score of 26 to denote PTSD.
Antepartum depression
Antepartum depression was assessed using the Patient Health Questionnaire (PHQ-9), a nine-item, self-reported depression measure from the Primary Care Evaluation of Mental Disorders (Kroenke et al. 2001; Spitzer et al. 1999 ) diagnostic instrument. The instrument was derived from the criteria of the DSM-IV and assessed nine depressive symptoms, namely anhedonia, depressed mood, trouble sleeping, feeling tired, change in appetite, guilt or worthlessness, trouble concentrating, feeling slowed down or restless, and suicidal thoughts, experienced over the last 2 weeks (14 days). The PHQ-9 score was calculated by assigning scores of 0, 1, 2, and 3 to the response categories of "not at all," "several days," "more than half the days", and "nearly every day," respectively. As a severity measure, the total score of PHQ-9 ranged from 0 to 27 with possible major depressive disorder (MDD) defined as total score ≥10 (Kroenke et al. 2001) . The PHQ-9 has been widely used for depression screening in adult primary care settings and hospital settings. It has been translated into at least 25 languages (Furukawa 2010; Flynn et al. 2011 ) and successfully used to measure depression severity among US African Americans, Asian/Chinese Americans, Latinos, and non-Hispanic Whites (Chen et al. 2006; ). The Spanish-language version of the PHQ-9 has been shown to be a reliable and efficient screening measure for depression severity in primary care (Wulsin et al. 2002; Zhong et al. 2014) , and it has been validated among both prenatal and postpartum women.
Serum BDNF assessments
Following structured interviews, maternal non-fasting blood samples were collected in 7-ml plain (red-top) vacutainer tubes. Blood samples were kept on wet ice and processed within 20 min of phlebotomy. The samples were centrifuged at 850g for 20 min at 4°C. Fractions were aliquoted into cryovials and stored at −80°C until analysis. Serum BDNF concentrations were measured using a competitive enzymelinked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) with intra-and inter-assay coefficients of variation both <8 %. All assays were performed without knowledge of maternal PTSD status.
Statistical analysis
The distribution of maternal socio-demographic characteristics and medical and reproductive histories according to antepartum PTSD status was examined. Since BDNF concentrations were not normally distributed, Wilcoxon sum-rank test was used to compare values across different groups. To estimate the association of antepartum PTSD with varying concentrations of BDNF, we categorized each subject according to quartiles determined by the distribution of serum BDNF concentrations among the entire study population. Logistic regression procedures were used to calculate maximum likelihood estimates of odds ratios (OR) and 95 % confidence intervals (95 % CI), adjusted for potential confounding factors. Confounders were defined as those factors which altered the unadjusted odds ratios by at least 10 %. Maternal age, parity, and early-pregnancy body mass index (BMI) were considered to be potential confounders. To assess comorbid antepartum PTSD and depression status in relation to serum BDNF concentrations, we categorized participants into the following four groups based on the combinations of these two disorders: (1) no PTSD and no depression; (2) no PTSD and yes depression (isolated depression); (3) yes PTSD and no depression (isolated PTSD); and (4) PTSD and depression. Women with no PTSD and no depression were used as the referent group. All the analyses were performed using Stata software version 12.0 (StataCorp LP, College Station, TX, USA). A two-tailed P value of <0.05 was considered to be statistically significant.
Results
Antepartum PTSD was prevalent in this cohort of low-income pregnant Peruvian women (37.4 %). Characteristics of study participants distributed according to PTSD symptomatology are summarized in Table 1 . Briefly, women with antepartum PTSD tended to be younger, to have more difficulty accessing basic foods, and to report that their pregnancy was unplanned, as compared with women without PTSD. Overall, approximately 27.6 % of the cohort had depression and approximately 19.9 % of participants had comorbid PTSD-depression. As shown in Table 2 , women with comorbid PTSD-depression were younger, less likely to be nulliparous, and less likely to have planned the current pregnancy compared to women without either condition.
We observed no significant differences in maternal early-pregnancy serum BDNF concentrations in terms of antepartum PTSD status (median [interquartile range], 21.15 [17.33-25.82] vs. 20.67 [17.27-24.70 ] ng/ml; P = 0.21). Estimated associations of antepartum PTSD status in relation to maternal early-pregnancy BDNF concentrations are shown in Table 3 . The adjusted ORs (95 % CIs) for antepartum PTSD were 1.20 (95 % CI 0.81-1.78), 1.24 (95 % CI 0.84-1.83), 1.38 (95 % CI 0.94-2.03), and 1.00 for successive quartiles (lowest to highest quartile), with the highest quartile as the referent group. There was no evidence of a statistically significant linear trend in odds of antepartum PTSD across decreasing quartiles of BDNF (P value for trend = 0.50 in the adjusted model). As shown in the bottom panel of Table 3 , compared to women with BDNF concentrations in the highest quartile (>25.38 ng/ml), women with lower concentrations (≤25.38 ng/ml, the lowest three quartiles combined) had no clear evidence of an increased odds of antepartum PTSD (OR = 1.35; 95 % CI 0.98-1.88) after adjustments for confounding factors.
We next evaluated maternal serum BDNF concentrations among women according to their antepartum PTSD and depression status (no PTSD or depression, isolated depression, isolated PTSD, and comorbid PTSD-depression). Median serum BDNF concentrations were lower among women with comorbid PTSD-depression as compared with women without either condition (median [interquartile range], 20.44 [16.97-24.30] vs. 21.35 [17.33-26 .01] ng/ml; P = 0.06), although the difference did not reach statistical significance. BDNF concentrations were essentially similar for the other three groups (Fig. 1) . Finally, we evaluated the odds of low serum BDNF concentrations (<25.38 vs. ≥25.38 ng/ml) in relation to isolated depression, isolated PTSD, and comorbid PTSD-depression using those with no PTSD and no depression as the referent group. Women with comorbid PTSDdepression had 1.52-fold increased odds of having lower serum BDNF concentration (<25.38 ng/ml) as compared with women who had neither disorders (OR = 1.52; 95 % CI 1.00-2.31). Compared with the referent group, women with isolated depression had a 1.83-fold increased odds of having lower serum BDNF concentrations, although this association did not reach statistical significance (OR = 1.83; 95 % CI 0.96-3.46). We observed no evidence of an association of reduced BDNF concentrations with isolated PTSD (OR = 1.20; 95 % CI 0.78-1.87) ( Table 4) .
Discussion and conclusion
The prevalence of antepartum PTSD and depression in this cohort of pregnant Peruvian women was 37.4 and 27.6 %, respectively. The prevalence of comorbid PTSD-depression was 19.9 %. This is the first study to take into account the comorbid occurrence of PTSD and depression and to assess serum BDNF concentrations in women with comorbid PTSDdepression. We found BDNF concentrations in early Due to missing data, the total sample size may not add up to 2928 a Mean ± SD (standard deviation) Twenty-nine participants were excluded due to missing information on the PHQ-9 (Patient Health Questionnaire-9) a Mean ± SD (standard deviation)
b For continuous variable, P value was calculated using one-way analysis of variance; for categorical variable, P value was calculated using chi-square test Table 3 Odds ratio (OR) and 95 % confidence interval (CI) for maternal serum brain-derived neurotrophic factor (BDNF, ng/ml) concentrations in early pregnancy in relation to post-traumatic stress disorder ( To the best of our knowledge, this is the first study to examine maternal serum BDNF concentrations in relation to antepartum PTSD while considering comorbid depression. We found no significant reduction in serum BDNF concentrations in pregnant Peruvian women with antepartum PTSD. Our findings are consistent with some prior studies of BDNF concentrations and PTSD in men, non-pregnant women, and children (Su et al. 2015; Simsek et al. 2015; Bonne et al. 2011; Molendijk et al. 2012) . For example, Bonne et al., in their study of 16 medication-free outpatients with chronic PTSD due to physical and/or sexual abuse or motor vehicle accidents (age, 36 ± 11.4 years), reported similar BDNF concentrations from cerebrospinal fluids between PTSD patients and healthy controls (1.00 ± 0.52 vs. 0.83 ± 0.44 pg/ml; P = 0.39) (Bonne et al. 2011) . Our results, however, differ from some previous reports that showed decreased BDNF concentrations in PTSD patients (Angelucci et al. 2014; Dell'Osso et al. 2009 ). Angelucci et al., in their study of 23 drug-free outpatients with PTSD and 19 outpatients with trauma exposure who have not developed PTSD, reported decreased serum BDNF concentrations in PTSD patients as compared to controls (4018.1 ± 359 vs. 4886.6 ± 180 pg/ml, P < 0.05) (Angelucci et al. 2014) . Dell'Osso et al. reported decreased plasma BDNF concentrations in patients with PTSD (N = 18) as compared to healthy controls (N = 18) (5.3 ± 1.1 vs. 7.4 ± 1.5 ng/ml; P < 0.001) (Dell'Osso et al. 2009 ).
Inconsistencies in results across studies may, in part, be attributable to differences in the type of assays and tissues (e.g., serum vs. plasma) used to measure BDNF concentrations. Further, differences in the study population characteristics including severity and the presence of comorbid Yes PTSD, Yes Depression Serum BDNF concentraƟons (ng/ml) Fig. 1 Concentrations of serum brain-derived neurotrophic factor (BDNF, ng/ml) in early pregnancy according to antepartum posttraumatic stress disorder (PTSD) and depression status, Lima, Peru (N = 933; 11 participants were excluded due to missing information on the PHQ-9 (Patient Health Questionnaire-9)) Eleven participants were excluded due to missing information on the PHQ-9 (Patient Health Questionnaire-9)
PTSD post-traumatic stress disorder, OR odds ratio, CI confidence interval a High concentrations were defined as "the fourth quartile"; low concentrations were defined as "the first three quartiles combined" psychiatric characteristics may account for some variations in results across studies. Lastly, failure to account for demographic, metabolic, and lifestyle characteristics known to be associated with BDNF concentrations may have contributed to residual confounding and variability on associations observed across studies. Observed associations of antepartum PTSD (and comorbid PTSD-depression) with decreased BDNF concentrations are biologically plausible. Briefly, chronic stress is known to impair various endocrine, physiological, and neuronal functions, and is often associated with higher vulnerability to psychiatric disorders and cognitive impairments (McEwen 2004; Warner-Schmidt and Duman 2006) . Available evidence indicates that BDNF may play a role in stress-related psychiatric disorders. For example, in animal studies, BDNF concentrations are decreased after chronic stress (Roceri et al. 2004; Murakami et al. 2005) . Further, serum BDNF concentrations are known to be reduced in stress-related major depressive disorders (Karege et al. 2002; Diniz et al. 2010; Shimizu et al. 2003) and this reduction appears to be mediated partly via stress-induced glucocorticoid release from adrenal glands (Smith et al. 1995) . Together, findings from human and animal studies suggest possible underlying biological mechanisms to support a possible role of altered BDNF synthesis in stress-related psychiatric disorders.
To the best of our knowledge, this is the first study to show that comorbid PTSD and depression is associated with reduced BDNF concentrations in pregnant women. These findings extend earlier reports and suggest that alterations in BDNF may be involved in the pathogenesis of stress-related mental disorders among pregnant women. BDNF may be a biomarker in stress-related mood disorders, particularly since several earlier studies have found decreased concentrations of serum BDNF in various stressrelated mental disorders, such as depression (Karege et al. 2002; Fung et al. 2015) and post-traumatic stress disorder (Bocchio-Chiavetto et al. 2010) .
